PROCEPT BioRobotics Targets 30%+ Revenue Growth Through BPH Leadership
Event summary
- PROCEPT BioRobotics hosted its 2026 Investor Day, outlining a multi-year financial outlook and strategic plan for long-term growth.
- The company expects 27-33% revenue growth in 2026 and 25-30% in 2027, driven by 39-48% procedure growth in 2026.
- Gross margins are projected to improve to 65% in 2026 and 68-70% in 2027, with positive adjusted EBITDA expected by Q4 2026.
- PROCEPT confirmed completion of all procedures in the WATER IV prostate cancer trial by mid-2026, ahead of schedule.
- Strategic focus includes procedure growth, disciplined pricing, commercial execution, and international expansion.
The big picture
PROCEPT BioRobotics is shifting its focus from establishing Aquablation therapy to driving leadership in BPH through a complete solution. The company's strong financial outlook and strategic initiatives aim to capitalize on the underpenetrated BPH market, with long-term growth drivers including international expansion and prostate cancer treatment applications. The projected revenue growth and improving margins reflect the company's disciplined approach to commercial execution and pricing.
What we're watching
- Procedure Growth
- Whether PROCEPT can sustain its projected 39-48% procedure growth in 2026 through patient-centric solutions and targeted education.
- Market Expansion
- The pace at which PROCEPT can expand into international markets and diversify into prostate cancer treatment.
- Profitability
- How quickly PROCEPT can achieve and maintain profitability, given its path to positive adjusted EBITDA by Q4 2026.
Related topics